Clinical Trial

A Study of Trilaciclib Combined With mFOLFIRINOX in the Treatment of Patients With Advanced Pancreatic Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated February 23, 2024 (before its estimated May 28, 2025 completion). Its status may not reflect the trial's current state.
Summary
To observe the incidence of chemotherapy-induced myelosuppression and the safety of Trilaciclib combined with mFOLFIRINOX in patients with advanced pancreatic cancer receiving first-line treatment.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-11-21.
Status change: Not Yet Recruiting → Recruiting 2024-02-21
Trial Details
NCT Number NCT06151262
Lead Sponsor The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Conditions Pancreatic Cancer
Enrollment 30 participants
Start Date 2024-01-20
Primary Completion 2025-05-28 (estimated)
Study Completion 2026-10-28 (estimated)
Updated on ClinicalTrials.gov 2024-02-23